Sameem Abedin, MD | Froedtert & the ...

Dr. Sameem M. Abedin

Claim this profile

Medical College of Wisconsin

Studies Acute Myeloid Leukemia
Studies Intestinal Maturation
14 reported clinical trials
33 drugs studied

Area of expertise

1

Acute Myeloid Leukemia

Sameem M. Abedin has run 9 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

FLT3 positive
D835 positive
RUNX1-RUNX1T1 negative
2

Intestinal Maturation

Sameem M. Abedin has run 4 trials for Intestinal Maturation. Some of their research focus areas include:

FLT3 positive
D835 positive
RUNX1-RUNX1T1 negative

Affiliated Hospitals

Image of trial facility.

Medical College Of Wisconsin

Image of trial facility.

The Medical College Of Wisconsin

Clinical Trials Sameem M. Abedin is currently running

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Recruiting

1 award

Phase 2

7 criteria

Image of trial facility.

OrcaGraft

for Blood Cancer

This trial is testing the safety and effectiveness of using specially prepared donor cells for patients with blood cancers. These patients are receiving a strong type of bone marrow transplant. The goal is to replace their damaged bone marrow with healthy cells from a donor to help them recover. Bone marrow transplantation (BMT) is a powerful strategy for the treatment of leukemia, aplastic anemia, congenital immunodeficiency, and autoimmune diseases.

Recruiting

1 award

Phase 1

More about Sameem M. Abedin

Clinical Trial Related

7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Sameem M. Abedin has experience with

  • Cyclophosphamide
  • Ruxolitinib
  • Venetoclax
  • Gilteritinib
  • Neihulizumab
  • Cytarabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sameem M. Abedin specialize in?

Is Sameem M. Abedin currently recruiting for clinical trials?

Are there any treatments that Sameem M. Abedin has studied deeply?

What is the best way to schedule an appointment with Sameem M. Abedin?

What is the office address of Sameem M. Abedin?

Is there any support for travel costs?